| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
185,611,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
6,246,627 |
Avg
Vol: |
2,847,643 |
| 52
Week Range: |
$23.99 - $23.99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Berstein David L |
Senior VP, Chief IP Officer |
• • – |
2013-03-25 |
4 |
S |
$18.87 |
$198,807 |
D/D |
(10,533) |
205,298 |
|
- |
|
| Dodion Pierre F |
SVP, Corp. Dev. & Operations |
• • – |
2013-03-25 |
4 |
S |
$18.87 |
$153,482 |
D/D |
(8,133) |
54,082 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2013-03-25 |
4 |
S |
$18.87 |
$244,079 |
D/D |
(12,933) |
114,271 |
|
- |
|
| Keane Raymond T |
SVP General Counsel & CCO |
• • – |
2013-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,333 |
64,680 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-03-22 |
4 |
D |
$19.38 |
$894,348 |
D/D |
(46,148) |
1,745,543 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
97,667 |
1,791,691 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2013-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
38,333 |
376,372 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2013-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,333 |
74,140 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2013-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,333 |
204,488 |
|
- |
|
| Berstein David L |
Senior VP, Chief IP Officer |
• • – |
2013-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
26,333 |
215,831 |
|
- |
|
| Dodion Pierre F |
SVP, Corp. Dev. & Operations |
• • – |
2013-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,333 |
62,215 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2013-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
32,333 |
127,204 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2013-03-22 |
4 |
D |
$19.38 |
$113,896 |
D/D |
(5,877) |
58,025 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2013-03-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,000 |
63,902 |
|
- |
|
| Duvall Martin J |
SVP, Commercial Operations |
• • – |
2013-03-22 |
4 |
S |
$19.53 |
$11,249 |
D/D |
(576) |
2,854 |
|
- |
|
| Keane Raymond T |
SVP General Counsel & CCO |
• • – |
2013-03-22 |
4 |
S |
$19.46 |
$45,423 |
D/D |
(2,334) |
38,347 |
|
- |
|
| Haluska Frank |
SVP, Clinical R&D, CMO |
• • – |
2013-03-22 |
4 |
S |
$19.46 |
$46,694 |
D/D |
(2,400) |
60,807 |
|
- |
|
| Dodion Pierre F |
SVP, Corp. Dev. & Operations |
• • – |
2013-03-22 |
4 |
S |
$19.46 |
$46,698 |
D/D |
(2,400) |
41,882 |
|
- |
|
| Berstein David L |
Senior VP, Chief IP Officer |
• • – |
2013-03-22 |
4 |
S |
$19.46 |
$31,135 |
D/D |
(1,600) |
189,498 |
|
- |
|
| Bollag Daniel M |
Sr. VP, Reg. Affairs & Quality |
• • – |
2013-03-22 |
4 |
S |
$19.46 |
$46,694 |
D/D |
(2,400) |
94,871 |
|
- |
|
| Clackson Timothy P |
President, R&D, CSO |
• • – |
2013-03-22 |
4 |
S |
$19.46 |
$129,718 |
D/D |
(6,667) |
338,039 |
|
- |
|
| Cantor Maria E |
SVP, Corporate Affairs |
• • – |
2013-03-22 |
4 |
S |
$19.45 |
$71,335 |
D/D |
(3,667) |
42,235 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-03-20 |
4 |
D |
$20.45 |
$328,529 |
D/D |
(16,065) |
1,694,024 |
|
- |
|
| Berger Harvey J MD |
Chairman & CEO |
• • – |
2013-03-20 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,000 |
1,710,089 |
|
- |
|
| Fitzgerald Edward M |
Executive VP, CFO |
• • – |
2013-03-20 |
4 |
D |
$20.45 |
$55,665 |
D/D |
(2,722) |
172,155 |
|
- |
|
703 Records found
|
|
Page 15 of 29 |
|
|
